Onyx Targeted In Shareholder Suit Over $10.4B Amgen Deal
Onyx Pharmaceuticals Inc. and its top brass on Thursday were hit with a shareholder class action alleging breach of fiduciary duty for allowing the drugmaker to be acquired by biotechnology mammoth...To view the full article, register now.
Already a subscriber? Click here to view full article